Objective: To identify causative genes for centronuclear myopathies (CNM), a heterogeneous group of rare inherited muscle disorders that often present in infancy or early life with weakness and hypotonia, using next-generation sequencing of whole exomes and genomes.
The centronuclear myopathies (CNM) are a group of clinically and genetically heterogeneous muscle disorders defined by the presence of one or more internalized nuclei in affected myofibers without excessive regeneration or additional structural abnormalities. [1] [2] [3] The clinical presentation ranges from severe hypotonia with respiratory insufficiency at birth, to late-onset mild muscle weakness, with clinical findings largely limited to the skeletal musculature. To date, mutations in 4 genes involved in either the assembly or function of triads, the specialized membrane structures sustaining the excitation-contraction coupling, 4 have been identified in CNM patients: MTM1 (myotubularin) in X-linked severe CNM (MIM 310400), DNM2 (dynamin 2) in autosomal dominant and sporadic cases (MIM 160150), BIN1 (amphiphysin 2) causing rare autosomal recessive disease (MIM 255200), and RYR1 (ryanodine receptor 1) associated with autosomal recessive and sporadic presentations. 5 Nevertheless, the genetic basis for disease remains unknown in a significant proportion of patients with clinicopathologic diagnoses of CNM (;20%), 5 hampering a complete understanding of the molecular mechanisms underlying the pathogenesis and genetic counseling in such families. To identify additional genes involved in these conditions, we performed whole-exome sequencing, or in one case whole-genome sequencing, on DNA from a cohort of 29 unrelated patients who presented to the research study with clinicopathologic diagnoses of CNM.
METHODS Standard protocol approvals, registrations, and patient consents. This study was approved by the institutional review board of Boston Children's Hospital. Written informed consent was obtained from all participants.
Subjects. The subjects were selected from a group of 121 neuromuscular patients with clinicopathologic diagnoses of CNM from referring neurologists and neuropathologists. Seventy of the patients were excluded for having known mutations in MTM1 (45 patients), DNM2 (21 patients), RYR1 (3 patients), or BIN1 (1 patient) identified by prior research or clinical testing. The remaining patients were prioritized based on the availability of sufficient DNA sample for NGS and follow-up analysis. After identification of putative gene mutations reported here, slides and images of muscle biopsies from the 5 patients with TTN mutations were reviewed in a blinded manner by one board-certified neuropathologist (M.W.L.) to independently establish a pathologic diagnosis for each case.
Whole-exome and whole-genome sequencing. Exome sequencing of 28 probands was performed by the IDDRC Core Next-Gen Sequencing Facility of Boston Children's Hospital and Harvard Medical School, in collaboration with Axeq Technologies. Samples were enriched for exomic sequences using the Illumina Exome Enrichment protocol and captured libraries were sequenced using Illumina HiSeq 2000 Sequencers. The reads were mapped to the human genome assembly UCSC hg19 using Burrows-Wheeler Alignment (BWA version 0.5.8, http://bio-bwa.sourceforge.net/). Single-nucleotide polymorphisms and small insertions/deletions were called with SAMtools (version 0.1.7, http://samtools. sourceforge.net/). DNA from a 29th proband was sequenced by Complete Genomics Standard Sequencing Service for wholegenome sequencing through the Gene Partnership Program at Boston Children's Hospital.
Indirect immunofluorescence analysis of muscle biopsies.
Frozen muscle sections were fixed in ice-cold acetone for 10 minutes, followed by immunostaining with titin N-terminal (Sigma SAB1400284) (epitope: first 111 amino acids), A-I junction (titin MIR antibody 6 ) (epitope: exons 256-258), C-terminal (Santa Cruz sc-271945) (epitope: last 300 amino acids), calpain 3 (Novocastra 2A12), ryanodine receptor (Sigma R128), aldolase A (AldoA) (Cell Signaling 3188), and anti-a-actinin (4D2) antibodies.
Hybrid minigene splicing assay. Exons of interest were cloned with their flanking introns into the pZW4 splicing reporter construct 7 between HpaI and KpnI restriction sites. The mutations at the donor or acceptor splice sites were introduced by site-directed mutagenesis. Wild-type or mutant hybrid minigene containing plasmids were transfected into HEK293 cells, followed by RNA extraction after 24 hours and reverse transcriptase-PCR using primers flanking the hybrid constructs.
Sodium dodecyl sulfate-gel electrophoresis of muscle proteins. Protein extracts from patient and control muscles were prepared as described, 8 separated by 1% agarose gel electrophoresis, and stained with Coomassie blue.
RESULTS Identification of TTN mutations by nextgeneration sequencing. On average, 88.7% of the total reads from whole-exome sequencing were uniquely aligned to the reference genome. The mean coverage rate of target regions was 94.47% and on average 86.77% of the target bases were covered by .103 reads for each exome. The annotated variants were filtered against variations reported on dbSNP132, 9 the 1000 Genomes project November 2010 edition, and the National Heart, Lung, and Blood Institute Exome Sequencing Project (http://evs.gs.washington. edu/EVS/) databases. Remarkably, 5 individuals were notable for all having 2 or more potentially pathogenic variants in one common gene, TTN, which was an excellent candidate CNM gene because of its critical role in maintaining sarcomeric structure and function (figure e-1A on the Neurology ® Web site at www. neurology.org). TTN encodes the giant sarcomeric protein titin that forms a myofibrillar backbone for the components of the contractile machinery, spanning the full distance from the Z-disk to the M-band in the sarcomere. [10] [11] [12] Encompassing 363 exons, TTN includes several regions subject to extensive differential splicing, producing a number of different isoforms in cardiac and skeletal muscles. 10, 13, 14 TTN mutations have previously been implicated in various cardiac and skeletal muscle diseases including adult-onset tibial muscular dystrophy, [15] [16] [17] limb-girdle muscular dystrophy 2J, 15, 18 hereditary myopathy with early respiratory failure, 19, 20 and earlyonset myopathy with fatal cardiomyopathy. 21 Heterozygous truncating mutations in TTN have also been shown to be a common cause of dilated cardiomyopathy, accounting for ;25% of cases in one large series. [22] [23] [24] [25] Mutations in various titin-associated proteins also disrupt the sarcomeric structure, leading to different neuromuscular diseases. 11, [26] [27] [28] [29] [30] [31] Based on these reasons, we hypothesized that the TTN mutations present in our 5 patients with CNM were likely to be causative for the disease. Although occasional fibers with internal nuclei have been reported in other muscle diseases with TTN mutations, 19 patients had a noteworthy cardiac phenotype, although the ages at last examination only ranged from 5 to 19 years. In addition, ophthalmoplegia, a common finding in the previously defined CNM cases, was not present. One patient (1044-1) was found to have moderately elevated serum creatine kinase levels and was considered to carry a clinical diagnosis of possible muscular dystrophy, but his clinical course was nonprogressive, and muscle pathology was distinctly nondystrophic and consistent with CNM, leading to referral by his clinician to this research study focused on CNM.
Histologic features of muscle biopsies. A blinded evaluation of the muscle biopsy slides by a single neuropathologist (M.W.L.) confirmed that all 5 biopsies were consistent with a pathologic diagnosis of CNM. All biopsies showed marked increase in the number of fibers with internal and central nuclei, ranging from 29% to 86%, compared with approximately 3% observed in healthy muscles ( figure 1, A-E ). In contrast to the typical findings of a single centrally placed nucleus in myofibers of patients with MTM1 or DNM2 mutations, nearly all cells in the biopsy from patient 966-1 contained multiple internalized nuclei, with 3 to 5 internalized nuclei in the majority of the fibers. Many fibers had multiple central nuclei arranged in a row ( figure 1G ). Adenosine triphosphatase staining revealed marked type I fiber hypotrophy and predominance (65%-85% type I fibers) ( figure 1H ).
Oxidative stains in one case (1044-1) demonstrated occasional fibers with core-like areas or sarcoplasmic clearing around centrally located nuclei, giving a "ring-like" appearance (figure 1, I and J). Central accumulation of oxidative stains, radial arrangements, or necklace fibers, which are often present in RYR1-, 32 DNM2-, 33, 34 and MTM1-related 35 CNM, respectively, were not observed. Moderate to focally severe increases in endomysial connective tissue and infiltrating adipose tissue, suggestive of a possible dystrophic etiology, were present particularly in the biopsy from patient 966-1, but these findings were associated with the presence of a myotendinous insertion, making the diagnostic relevance of that observation uncertain. No intracytoplasmic inclusions or subsarcolemmal depositions were identified by Gomori trichrome staining ( figure 1K ). In addition, alkaline phosphatase staining and immunolabeling with an embryonic myosin heavy chain antibody showed no evidence of regenerating fibers. Electron microscopy demonstrated severe myofibrillar disorganization in fibers with internal nuclei and varying degrees of Z-disk streaming (figure 1, L-Q).
Mutation analysis. Sanger sequencing in patients and parents validated that all 5 individuals were compound heterozygotes for different disruptive TTN mutations ( Two mutations identified in our patients, c.100185delA and c.32854G.C, have previously been associated with tibial muscular dystrophy and adult-onset cardiomyopathy, respectively, in the heterozygous state. 16, 25 Tibial muscular dystrophy presents in the fifth to sixth decades of life with preferential weakness in the tibialis anterior muscles. 16 The mother of patient 1044-1, heterozygous for c.100185delA mutation, was adopted with no known family history, and had no clinical signs of muscle weakness at the age of 34 years. Extensive cardiac and muscle examination performed on the father of patient 314-1, heterozygous for c.32854G.C mutation, showed no evidence of cardiomyopathy or skeletal myopathy at the age of 46.5 years. However, similar clinical examinations of this patient's 44-year-old mother, heterozygous for c.37112-1G.A mutation, revealed mild subclinical cardiac and skeletal myopathies, suggesting that this mutation may have a dominant effect for both diseases. The parents heterozygous for the remaining mutations had no reported skeletal muscle or cardiac defects, although extensive cardiac examination has not been performed since identification of these mutations.
Immunofluorescence analysis on patient muscle biopsies.
To determine whether these mutations altered titin structure and its localization in the sarcomere, we performed indirect immunofluorescence analysis on muscle biopsies available from patients 314-1, 1044-1, and 1093-1 using 3 epitope-specific antibodies directed against the N-terminal, A-I junction, or C-terminal regions of titin ( figure 2A) . Cryosections from the 3 patients and 2 age-matched controls were immunostained with each of the titin antibodies and an a-actinin-2 antibody to visualize sarcomeric organization. All patient muscles showed normal sarcomeric labeling with the titin N-terminal and A-I junction antibodies, indicating that titin was integrated into the sarcomeres and its structure was intact up to the level of the A-I junction ( figure 2C ). On the other hand, the antibody that recognizes an epitope located at the C-terminal end of titin showed a complete loss of this site in all 3 patient muscles. The C-terminal region of titin contains 1 of the 2 binding sites for calpain 3 (CAPN3). 11, 21 Binding of calpain 3 to the M-line region of titin is required for its stabilization, as mutations in this region of titin cause a decrease in the amount of calpain 3 in the muscle. 19, 21, 36 Patient muscles demonstrated reduced or absent immunostaining with a calpain 3 antibody, indicating a loss of the calpain 3 binding region on the mutant titin proteins ( figure 2C ). Altogether, these results suggested that all patient muscles analyzed had truncated titin proteins lacking a significant portion of their Cterminal regions.
Because calpain 3 is necessary for the proper recruitment of AldoA and ryanodine receptors to the triads, 37 we also investigated the level and localization of AldoA and ryanodine receptors in patient muscles. While the labeling in muscle from patients 1044-1 and 1093-1 for both proteins was comparable with the controls, muscle from patient 314-1 showed reduced immunostaining for AldoA, consistent with the fact that mutations in this patient lie in the vicinity of the titin N2-line region, where AldoA-associated calpain 3 interacts with titin at the triads (figure e-2). 37 Splicing assay. To further support our interpretation of potential pathogenicity for several of these mutations, we examined the possible effects of TTN mutations that were predicted to cause splicing defects. Four mutations were found to reduce the consensus splice site agreement to background levels (table e-1). Two of these mutations were present in patient 314-1. Because we had a limited amount of tissue specimen available from this patient, we used an in vitro hybrid minigene splicing assay to test whether the mutations altered splicing ( figure 2D ). The c.32854G.C mutation within a donor splice site resulted in skipping of exon 168, whereas the c.37112-1G.A mutation disrupting the consensus acceptor splice site of exon 192 caused the majority of transcripts to remain unspliced, as well as skipping of exon 192 or retaining of intron 191 in a subset of transcripts ( figure 2E ). Because all of these resulting transcripts are out of frame, they would either become targets of nonsense-mediated decay or when translated produce truncated titin proteins.
Gel electrophoresis of patient muscle proteins. To establish whether the mutations were indeed associated with reduced titin size and/or quantity, we analyzed titin proteins in patient muscles by sodium dodecyl sulfate-agarose gel electrophoresis ( figure 3 ). While the size of the largest titin isoform in the muscle of patient 1044-1 was not significantly different from the full-length titin in the control human soleus anti-a-actinin antibodies are presented in the inset lower right panels where the titin C-terminal or calpain 3 antibodies showed no signal. (D) Overview of the hybrid minigene splicing assay. Wild-type exon 168 and 192 (numbering based on N2A isoform) were cloned with their flanking introns into the pZW4 splicing reporter construct between HpaI and KpnI restriction sites. The mutations at the donor or acceptor splice sites were introduced by site-directed mutagenesis. Wild-type or mutant hybrid minigene containing plasmids were transfected into HEK293 cells, followed by RNA extraction and reverse transcriptase-PCR using primers flanking the hybrid constructs. (E) Results of the hybrid minigene splicing assay. The minigenes containing wild-type exon 168 or exon 192 were spliced correctly. The c.32854G.C mutation at the donor splice site of exon 168 caused exon skipping (left panel). The c.37112-1G.A mutation at the acceptor splice site of exon 192 resulted in the majority of transcripts to remain unspliced, as well as exon skipping or intron retention in a subset of transcripts (right panel). Scale bar 5 40 mm. For 5 forward; mut 5 mutation; Pt 5 patient; Rev 5 reverse; WT 5 wild-type. muscle (3.8 MDa), the patient had a second protein band with an estimated molecular mass of 2.7 MDa (figure 3, left lane) and a minor amount of T2. T2 is one of the most frequently observed degradation products of titin that contains titin's A-band segment and a small proportion of the I-band segment with a total molecular mass of ;2.1 MDa. 38 We suspect that the ;3.8-MDa isoform expressed in patient 1044-1 is likely the maternal allele product lacking only the last 21 amino acids, because the resulting protein size difference cannot be detected on the agarose gels, which have a resolution in the ;4-MDa range of less than ;0.1 MDa. The 2.7-MDa protein could be the paternal allele product with a nonsense mutation in exon 326, resulting in a truncated protein with a predicted molecular mass of 2.7 MDa. Patient 1093-1 had 2 titin bands that were significantly smaller than the full-length isoform, one with an estimated molecular mass of 3.5 MDa, and a second of ;2.3 MDa. The maternal allele of patient 1093-1 has a frameshift mutation in exon 298 resulting in a predicted protein with a molecular mass of ;2 MDa, and the paternal allele has a splice mutation in the I-band region of the molecule. We speculate that the paternal and maternal alleles produce the 3.5-MDa and the ;2.3-MDa proteins, respectively, with the discordance between predicted and observed molecular masses possibly explained by the uncertainty in estimating the molecular mass of megadalton-sized proteins on gels. Interestingly, patient 1093-1 also had reduced nebulin levels, the second-largest sarcomeric protein and a key component of the skeletal muscle thin filament. 39 Mutations in nebulin are known to cause nemaline myopathy, another form of congenital myopathy defined by muscle weakness and the presence of nemaline rods in the muscle biopsy. Patients with reduced nebulin levels have shorter thin filaments and altered sarcomeric organization. 40 While the absence of nemaline rods in the muscle of patient 1093-1 excluded a diagnosis of nemaline myopathy, the disease may have been exacerbated by the secondary reduction of nebulin. DISCUSSION We have identified compound heterozygous TTN mutations that all truncate or disrupt the predominant skeletal muscle isoforms of titin in 5 unrelated patients presenting with congenital myopathies diagnosed as CNM. Although mutations of MTM1 and DNM2 classically result in single and centrally placed nuclei, multiple internal nuclei, such as seen here, are more common in CNM due to RYR1 and BIN1 mutations. Thus, although one could retrospectively argue whether these 5 cases should really be classified as CNM, the fact remains that the referring neuropathologists had classified them as such, making this a useful categorization from a practical standpoint. Our results suggest that the different TTN mutations in our patients cause truncated proteins resulting in titin molecules that are devoid of the functions performed by titin's M-band segment, including structural and mechano-sensing roles. The discovery of TTN mutations associated with excessive central nucleation, reminiscent of CNM, does not necessarily indicate similar pathogenetic mechanisms. The 4 previously known CNM genes all encode proteins with a common functional theme: triad structure and function. On the other hand, titin is required for sarcomere assembly and keeping the contractile apparatus in place by providing binding sites for numerous components of the excitation-contraction coupling machinery. The electron micrographs of patient muscles show disintegrated sarcomeres with disrupted I-and A-band regions in fibers with central nuclei, suggesting that the lack of interaction sites for various titin-binding partners may cause failure to maintain the normal sarcomeric structure. Furthermore, we observed a reduction in the levels of calpain 3 and nebulin, 2 proteins that interact with titin, raising the possibility that the secondary reduction in their levels may contribute to the disease pathogenesis. Our results have important implications for guiding the clinical care of patients with CNM carrying TTN mutations. Mutations identified in various regions of TTN are known to cause adult-onset cardiomyopathy, with an average age of diagnosis at 38 years. 25 The oldest patient in our study was 19 years old when last followed. Because many of the mutations identified in our patients with CNM are also present in cardiac titin isoforms, these patients, and their parents, should be closely monitored for potential cardiac issues in the future. 
